Sugi Predict
/ Targets
/ BRD2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BRD2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
PHASE3 | COMPLETED |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes |
PHASE1/PHASE2 | COMPLETED |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
PHASE2 | COMPLETED |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma |
PHASE1/PHASE2 | RECRUITING |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Vorinostat in Children |
PHASE1/PHASE2 | COMPLETED |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation |
PHASE2 | RECRUITING |
| Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation |
PHASE2 | UNKNOWN |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis |
PHASE1/PHASE2 | RECRUITING |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
PHASE1 | RECRUITING |
| A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions |
PHASE1 | COMPLETED |
| Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load |
PHASE1 | COMPLETED |
| A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 Under Fasting Conditions in Healthy Adult Volunteers |
PHASE1 | COMPLETED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors |
PHASE1 | UNKNOWN |
| A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. |
PHASE1 | COMPLETED |
| Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor |
nan | NO_LONGER_AVAILABLE |
| A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL |
nan | RECRUITING |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors |
nan | UNKNOWN |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia |
nan | COMPLETED |
| Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. |
nan | UNKNOWN |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a BRD2 binder may also engage these)